Clinical trial data demonstrate that weight loss typically follows a predictable pattern: rapid initial loss during the first 12 to 20 weeks, followed by continued but slower loss until approximately 60 to 72 weeks, after which weight generally stabilizes
By combining short-acting and long-acting secretagogues with a regenerative peptide, the 4X Blend supports studies on regulation, recovery, and repair
70 (Supplement_1): 106OR [31] Innovent Biologics Clinical Data Update Mazdutide (IBI362) Higher Dose 9mg Phase 2 Clinical study in obesity, May 11, 2023
Many patients experience greater average weight loss with tirzepatide, although individual results can differ
The tradeoff: tirzepatide is newer with less long-term safety data than semaglutide, though its profile to date looks equally favorable